Radioimmunotherapy for B-cell lymphoma : Y⁹⁰ ibritumomab tiuxetan and I¹³¹ tositumomabDAVIES, A. J.Oncogene (Basingstoke). 2007, Vol 26, Num 25, pp 3614-3628, issn 0950-9232, 15 p.Article

Subsequent therapy can be administered after tositumomab and iodine 1-131 tositumomab for non-hodgkin lymphomaDOSIK, Alan D; COLEMAN, Morton; VALLABHAJOSULA, Shankar et al.Cancer. 2006, Vol 106, Num 3, pp 616-622, issn 0008-543X, 7 p.Article

La radio-immunothérapie des cancers = Radioimmunotherapy of cancersLEVEQUE, D; MONTEIRO, M.-C; DETOUR, J et al.Journal de pharmacie clinique (Paris). 2005, Vol 24, Num 3, pp 139-144, issn 0291-1981, 6 p.Article

Anti-CD20 monoclonal antibody therapy in multiple myelomaKAPOOR, Prashant; GREIPP, Patricia T; MORICE, William G et al.British journal of haematology. 2008, Vol 141, Num 2, pp 135-148, issn 0007-1048, 14 p.Article

Radioimmunotherapy for treatment of b-cell lymphomas and other hematologic malignanciesPARK, Steven I; PRESS, Oliver W.Current opinion in hematology. 2007, Vol 14, Num 6, pp 632-638, issn 1065-6251, 7 p.Article

¹³¹I-Tositumomab therapy as initial treatment for follicular lymphomaKAMINSKI, Mark S; TUCK, Melissa; WAHL, Richard L et al.The New England journal of medicine. 2005, Vol 352, Num 5, pp 441-449, issn 0028-4793, 9 p.Article

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximabHORNING, Sandra J; YOUNES, Anas; JAIN, Vinay et al.Journal of clinical oncology. 2005, Vol 23, Num 4, pp 712-719, issn 0732-183X, 8 p.Article

Arming antibodies : prospects and challenges for immunoconjugates : Antibody engineering and manufactureWU, Anna M; SENTER, Peter D.Nature biotechnology. 2005, Vol 23, Num 9, pp 1137-1146, issn 1087-0156, 10 p.Article

Monoclonal antibodies conjugated with radioisotopes for the treatment of non-Hodgkin's lymphomaBUSH, Sherri.Seminars in oncology nursing. 2002, Vol 18, Num 1, pp 16-21, issn 0749-2081, SUP1Article

OUTCOMES OF PATIENTS WITH NON-HODGKIN'S LYMPHOMA TREATED WITH BEXXAR WITH OR WITHOUT EXTERNAL-BEAM RADIOTHERAPYSMITH, Kristy; BYER, Gracie; MORRIS, Christopher G et al.International journal of radiation oncology, biology, physics. 2012, Vol 82, Num 3, pp 1122-1127, issn 0360-3016, 6 p.Article

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphomaDAVIES, A. J; ROHATINER, A. Z. S; MATHER, S. J et al.Journal of clinical oncology. 2004, Vol 22, Num 8, pp 1469-1479, issn 0732-183X, 11 p.Article

Antibody-based therapy of non-Hodgkin's lymphomaFORAN, James M.Baillière's best practice & research. Clinical haematology. 2002, Vol 15, Num 3, pp 449-465, issn 1521-6926, 17 p.Article

The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomabWAHL, Richard L.Seminars in oncology. 2003, Vol 30, Num 2, pp 31-38, issn 0093-7754, 8 p., SUP4Article

Outpatient radioimmunotherapy with Bexxar: Closed, clean air reservoir minimizes personnel radiation exposureHARWOOD, Steven J; GIBBONS, Linda K; GOLDNER, Pamela J et al.Cancer. 2002, Vol 94, Num 4, pp 1358-1362, issn 0008-543X, SUPConference Paper

Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemiaLAURIA, Francesco; LENOCI, Mariapia; TOZZI, Monica et al.Haematologica (Roma). 2001, Vol 86, Num 10, pp 1046-1050, issn 0390-6078Article

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomabKAMINSKI, Mark S; RADFORD, John A; GREGORY, Stephanie A et al.Journal of clinical oncology. 2005, Vol 23, Num 31, pp 7985-7993, issn 0732-183X, 9 p.Article

Traitement par anticorps monoclonaux dans les lymphomes et la leucémie lymphoïde chronique = Treatment of lymphomas and chronic lymphocytic leukemia by monoclonal antibodiesROSSI, J.-F.Oncologie (Paris). 2003, Vol 5, Num 1, pp 43-49, issn 1292-3818, 7 p.Article

Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomabHOHENSTEIN, Maribeth A; AUGUSTINE, Samuel C; RUTAR, Frank et al.Seminars in oncology. 2003, Vol 30, Num 2, pp 39-49, issn 0093-7754, 11 p., SUP4Article

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activationBEERS, Stephen A; CHAN, Claude H. T; JAMES, Sonya et al.Blood. 2008, Vol 112, Num 10, pp 4170-4177, issn 0006-4971, 8 p.Article

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasFISHER, Richard I; KAMINSKI, Mark S; WAHL, Richard L et al.Journal of clinical oncology. 2005, Vol 23, Num 30, pp 7565-7573, issn 0732-183X, 9 p.Article

Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndromeHEELAN, Bridget T; TORMEY, Vincent; AMLOT, Peter et al.British journal of haematology. 2002, Vol 118, Num 4, pp 1078-1081, issn 0007-1048Article

Improving the Efficacy of Radioimmunotherapy for Non-Hodgkin LymphomasPALANCA-WESSELS, M. Corinna A; PRESS, Oliver W.Cancer. 2010, Vol 116, Num 4, pp 1126-1133, issn 0008-543X, 8 p., SUPConference Paper

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + ¹³¹Iodine—TositumomabPRESS, Oliver W; UNGER, Joseph M; MALONEY, David G et al.Clinical cancer research (Print). 2013, Vol 19, Num 23, pp 6624-6632, issn 1078-0432, 9 p.Article

Immunotherapy in non-Hodgkin's lymphoma: treatment advancesFISHER, Richard I.Seminars in oncology. 2003, Vol 30, Num 2, issn 0093-7754, 50 p., SUP4Serial Issue

Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cellsHAMMADI, Mariam; YOUINOU, Pierre; TEMPESCUL, Adrian et al.Haematologica (Roma). 2012, Vol 97, Num 2, pp 288-296, issn 0390-6078, 9 p.Article